Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-043573
Filing Date
2025-05-01
Accepted
2025-05-01 17:20:16
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm252538d2_defa14a.htm DEFA14A 15820
2 GRAPHIC tm252538d2_defa14aimg001.jpg GRAPHIC 255007
3 GRAPHIC tm252538d2_defa14aimg002.jpg GRAPHIC 55812
4 GRAPHIC tm252538d2_defa14aimg003.jpg GRAPHIC 176500
5 GRAPHIC tm252538d2_defa14aimg004.jpg GRAPHIC 98392
  Complete submission text file 0001104659-25-043573.txt   816773
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39202 | Film No.: 25904414
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)